The development of an effective AIDS vaccine remains one of the highest priorities in HIV research. Studies of HIV pathogenesis, vaccine design and antiretroviral treatments require an appropriate animal model. However, the existing SIV/macaque model has major limitations since (i) prototypic SIVmac strains are too pathogenic, (ii) do not represent mucosally transmitted viruses, and (iii) have been extensively passaged in vitro and in vivo. We have recenfiy identified a large set of new SIVsmm strains which mirror HIV-1 group M viruses in their genetic diversity. Moreover, preliminary in vivo results show that infection of RMs with these SIVsmm strains more closely reproduces the natural history of HIV-1 in humans. Within this HIVRAD consortium, we thus propose to use these new SIVsmm strains to generate new (molecularly cloned) challenge viruses for AIDS vaccine and pathogenesis studies. Project 1 will use a dose-escalafion strategy to infect 21 Indian rhesus macaques (RMs) with genetically diverse SIVsmm strains using intravenous (iv), intrarectal (ir) and intravaginal (ivag) routes. Project 2 will then employ single genome amplificafion (SGA) techniques to infer, and subsequenfiy clone, transmitted/founder (T/F) virus(es) from all of these animals. Following detailed in vitro characterization, a subset of clones will be selected for in vivo competifion (n=18) and pathogenesis (n=8) studies which will be performed by Project 1.
Specific Aims i nclude: 1. To generate high titer plasma stocks of genefically divergent SIVsmm strains without in vitro adaptafion for subsequent mucosal and intravenous transmission studies. 2. To infect RMs by intravenous, intrarectal and intravaginal routes with physiologically relevant doses of genetically divergent SIVsmm strains to allow for the identification of transmitted founder (T/F) viruses: 3.;Tp identify SIVsmm clones with, preferenfial mucosal transmissibllity and replication fitness by conducting an in vivo compefition experiment. 4. To characterize the selected SIVsmm clones for in vivo replication kinefics, pathogenicity and suitability as vaccine challenge stocks. We expect these studies to generate new infecfious molecular clones of SIVs with biological properties that more faithfully recapitulate the transmission, pathogenic and diversity of HIV-1 in humans.

Public Health Relevance

This project will generate new viral stocks and virological reagents critically needed to elucidate the molecular and cellular events that are responsible for HIV/SIV transmission across rectal and vaginal/cervical mucosa and thus eliminate a major roadblock to AIDS vaccine development.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RB-A)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pennsylvania
United States
Zip Code
Policicchio, Benjamin B; Xu, Cuiling; Brocca-Cofano, Egidio et al. (2016) Multi-dose Romidepsin Reactivates Replication Competent SIV in Post-antiretroviral Rhesus Macaque Controllers. PLoS Pathog 12:e1005879
Raehtz, Kevin; Pandrea, Ivona; Apetrei, Cristian (2016) The well-tempered SIV infection: Pathogenesis of SIV infection in natural hosts in the wild, with emphasis on virus transmission and early events post-infection that may contribute to protection from disease progression. Infect Genet Evol 46:308-323
Mason, Rosemarie D; Welles, Hugh C; Adams, Cameron et al. (2016) Targeted Isolation of Antibodies Directed against Major Sites of SIV Env Vulnerability. PLoS Pathog 12:e1005537
Bailey, Adam L; Lauck, Michael; Ghai, Ria R et al. (2016) Arteriviruses, Pegiviruses, and Lentiviruses Are Common among Wild African Monkeys. J Virol 90:6724-6737
Bailey, Adam L; Lauck, Michael; Sibley, Samuel D et al. (2016) Zoonotic Potential of Simian Arteriviruses. J Virol 90:630-5
Pandrea, Ivona; Xu, Cuiling; Stock, Jennifer L et al. (2016) Antibiotic and Antiinflammatory Therapy Transiently Reduces Inflammation and Hypercoagulation in Acutely SIV-Infected Pigtailed Macaques. PLoS Pathog 12:e1005384
Li, Hui; Wang, Shuyi; Kong, Rui et al. (2016) Envelope residue 375 substitutions in simian-human immunodeficiency viruses enhance CD4 binding and replication in rhesus macaques. Proc Natl Acad Sci U S A 113:E3413-22
Langer, Simon M; Hopfensperger, Kristina; Iyer, Shilpa S et al. (2015) A Naturally Occurring rev1-vpu Fusion Gene Does Not Confer a Fitness Advantage to HIV-1. PLoS One 10:e0142118
Barbian, Hannah J; Decker, Julie M; Bibollet-Ruche, Frederic et al. (2015) Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas. MBio 6:
Policicchio, Benjamin B; Pandrea, Ivona; Apetrei, Cristian (2015) Population Bottlenecks and Pathogen Extinction: ""Make This Everyone's Mission to Mars, Including Yours"". J Virol 89:8104-6

Showing the most recent 10 out of 23 publications